Format

Send to

Choose Destination
Mol Pharm. 2018 Jul 2;15(7):2539-2547. doi: 10.1021/acs.molpharmaceut.8b00014. Epub 2018 Jun 18.

Cyclosporine A-Loaded Nanocarriers for Topical Treatment of Murine Experimental Autoimmune Uveoretinitis.

Author information

1
Department of Ophthalmology and Ophtha-Lab , St. Franziskus Hospital , Münster 48145 , Germany.
2
Apidel SA , Geneva 1201 , Switzerland.
3
School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva 1221 , Switzerland.
4
Department of Ophthalmology, Clinic for Diseases of the Anterior Segments of the Eyes , Essen University Hospital , Essen 45147 , Germany.
5
University of Duisburg-Essen , Essen 47057 , Germany.

Abstract

In the present study, tissue distribution and the therapeutic effect of topically applied cyclosporine A (CsA)-loaded methoxy-poly(ethylene-glycol)-hexyl substituted poly(lactic acid) (mPEGhexPLA) nanocarriers (ApidSOL) on experimental autoimmune uveitis (EAU) were investigated. The CsA-loaded mPEGhexPLA nanocarrier was tolerated well locally and showed no signs of immediate toxicity after repeated topical application in mice with EAU. Upon unilateral CsA treatment, CsA accumulated predominantly in the corneal and sclera-choroidal tissue of the treated eye and in lymph nodes (LN). This regimen reduced EAU severity in treated eyes compared to PBS-treated controls. This improvement was accompanied by reduced T-cell count, T-cell proliferation, and IL-2 secretion of cells from ipsilateral LN. In conclusion, topical treatment with CsA-loaded mPEGhexPLA nanocarriers significantly improves the outcome of EAU.

KEYWORDS:

T-cells; cyclosporine; drug delivery; micelles; nanocarrier; ophthalmics; uveitis

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center